A number of other equities research analysts have also recently commented on ZTS. Guggenheim reaffirmed a buy rating and issued a $60.00 price target on shares of Zoetis in a report on Monday, July 18th. Barclays PLC lifted their price target on shares of Zoetis from $45.00 to $49.00 and gave the stock an equal weight rating in a report on Thursday, August 4th. Citigroup Inc. lifted their price target on shares of Zoetis from $50.00 to $53.00 and gave the stock a neutral rating in a report on Thursday, August 4th. Credit Suisse Group AG reaffirmed an outperform rating and issued a $60.00 price target on shares of Zoetis in a report on Tuesday, August 23rd. Finally, Argus lifted their price target on shares of Zoetis from $54.00 to $58.00 and gave the stock a below average rating in a report on Friday, September 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $55.50.
Shares of Zoetis (NYSE:ZTS) opened at 50.18 on Friday. Zoetis has a 12 month low of $38.26 and a 12 month high of $53.14. The company’s 50-day moving average price is $51.25 and its 200-day moving average price is $49.01. The firm has a market cap of $24.84 billion, a P/E ratio of 39.08 and a beta of 1.01.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. Zoetis’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 EPS. On average, analysts predict that Zoetis will post $1.91 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be given a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.76%. Zoetis’s dividend payout ratio (DPR) is presently 29.69%.
In related news, insider Heidi C. Chen sold 32,097 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total value of $1,636,305.06. Following the completion of the transaction, the insider now directly owns 46,060 shares in the company, valued at $2,348,138.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Fenton sold 13,870 shares of the company’s stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total transaction of $710,837.50. Following the completion of the transaction, the insider now owns 17,719 shares of the company’s stock, valued at $908,098.75. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in shares of Zoetis by 114.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,738,248 shares of the company’s stock valued at $414,717,000 after buying an additional 4,656,765 shares during the period. Alliancebernstein L.P. raised its position in shares of Zoetis by 49.9% in the second quarter. Alliancebernstein L.P. now owns 7,634,826 shares of the company’s stock valued at $362,349,000 after buying an additional 2,542,023 shares during the period. Vanguard Group Inc. raised its position in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock valued at $1,415,256,000 after buying an additional 1,812,428 shares during the period. Marsico Capital Management LLC raised its position in shares of Zoetis by 321.7% in the second quarter. Marsico Capital Management LLC now owns 2,106,745 shares of the company’s stock valued at $99,986,000 after buying an additional 1,607,218 shares during the period. Finally, Emerald Acquisition Ltd. bought a new position in shares of Zoetis during the second quarter valued at about $69,154,000. Institutional investors own 93.12% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.